Last Posted: Sep 24, 2020
- Genetic profiling of primary and secondary tumors from patients with lung adenocarcinoma and bone metastases reveals targeted therapy options.
Huang Long et al. Molecular medicine (Cambridge, Mass.) 2020 Sep 26(1) 88
- Whole Exome Profiling of NSCLC Among African Americans.
Arauz Rony F et al. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2020 Sep
- Genetic features and application value of next generation sequencing in the diagnosis of synchronous multifocal lung adenocarcinoma.
Chen Xiaoyan et al. Oncology letters 2020 Sep 20(3) 2829-2839
- The Underlying Tumor Genomics of Predominant Histologic Subtypes in Lung Adenocarcinoma.
Caso Raul et al. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2020 Aug
- Prognostic value of TP53 co-mutation status combined with EGFR mutation in patients with lung adenocarcinoma.
Wang Feng et al. Journal of cancer research and clinical oncology 2020 Aug
- Genetic determinants of lung cancer prognosis in never smokers: A pooled analysis in the International Lung Cancer Consortium.
Brhane Yonathan et al. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2020 Jul
- Identification of a 5-Gene Metabolic Signature for Predicting Prognosis Based on an Integrated Analysis of Tumor Microenvironment in Lung Adenocarcinoma.
Yu Xiaolin et al. Journal of oncology 2020 20205310793
- The prognostic value of a Methylome-based Malignancy Density Scoring System to predict recurrence risk in early-stage Lung Adenocarcinoma.
Yang Lu et al. Theranostics 2020 10(17) 7635-7644
- Clinical Utility of Reflex Ordered Testing for Molecular Biomarkers in Lung Adenocarcinoma.
Anand Kartik et al. Clinical lung cancer 2020 May
- Undetectable circulating tumor DNA levels correlate with low risk of recurrence/metastasis in postoperative pathologic stage I lung adenocarcinoma patients.
Yang Weixiong et al. Lung cancer (Amsterdam, Netherlands) 2020 Jun 146327-334
Rare Disease PHGKB is an online, continuously updated, searchable database of published scientific literature, CDC and NIH resources, and other information that address the public health impact and translation of genomic and other precision health discoveries into improved health outcomes related to rare diseases...more
- NIH Information (2)
- COVID-19 (13)
- Human Genome Epidemiologic Studies (943)
- GWAS Studies (8)
- Human Genomics Translation/Implementation Studies (103)
- Genomic Tests Evidence Synthesis (9)
- Genomic Tests Guidelines (2)
- Tier-Classified Guidelines (2)
- Non-Genomics Precision Health (5)
- Reviews/Commentaries (12)
Selected Rare Diseases
- Alpha-1 Antitrypsin Deficiency
- Amyotrophic Lateral Sclerosis
- Brugada Syndrome
- Cerebral Palsy
- Cystic Fibrosis
- Duchenne Muscular Dystrophy
- Erythema Multiforme
- Familial Mediterranean Fever
- Fragile X Syndrome
- Gaucher Disease
- Graves Disease
- Huntington Disease
- Myasthenia Gravis
- Retinitis Pigmentosa
- Severe Combined Immunodeficiency
Disclaimer: Articles listed in the Public Health Knowledge Base are selected by the CDC Office of Public Health Genomics to provide current awareness of the literature and news. Inclusion in the update does not necessarily represent the views of the Centers for Disease Control and Prevention nor does it imply endorsement of the article's methods or findings. CDC and DHHS assume no responsibility for the factual accuracy of the items presented. The selection, omission, or content of items does not imply any endorsement or other position taken by CDC or DHHS. Opinion, findings and conclusions expressed by the original authors of items included in the update, or persons quoted therein, are strictly their own and are in no way meant to represent the opinion or views of CDC or DHHS. References to publications, news sources, and non-CDC Websites are provided solely for informational purposes and do not imply endorsement by CDC or DHHS.